India, Sept. 15 -- ImmuPharm PLC (IMM.L), a clinical-stage specialty drug company, on Tuesday reported interim financial results for the six months ending June 30, 2026. Loss for the half-year period widened due to a change in fair value of a particular asset.
The company pipeline includes P140 (lupuzor), an immunonormalizer developed to modulate abnormal immune activity; Kapiglucagon for regulating glucagon and function of the pancreas; BioAMB for treating difficult fungal infections, and BioCIN for difficult bacterial infections.
H1 Financial Highlights:
ImmuPharm's loss before taxation climbed to £4.70 million in the first half of 2026, considerably more than the £1.94 million reported in the same period of 2025. This was at...